Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Phase 4

Completed

• Conditions: Infertility
• Interventions: Drug: Progevera; Drug: Orgalutran

• Registration Number: NCT02796105
• Lead Sponsor: Fundació Privada Eugin

Brief Summary

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2016-06-07
• Study First Submitted QC: 2016-06-09
• Study First Posted: 2016-06-10
• Primary Completion: 2017-07
• Study Completion: 2017-07-10
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-12
• Last Update Posted: 2017-09-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 232

Inclusion Criteria

• Oocyte donors included in the oocyte donation program of Clinica EUGIN.
• 1st oocyte donation cycle at Clínica EUGIN.

Exclusion Criteria

• Polycistic Ovarian syndrome (PCOs).
• Estradiol levels on day 2 of menstrual cycle >70 pg/ml.
• Hormone treatments up to 3 months before the oocyte donation cycle.
• Medical contraindication to the treatments used in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Progevera	Progevera	Progevera 10 mg
Orgalutran	Orgalutran	Orgalutran 0.25 mg

Primary Outcome Measures

Name	Time	Method
donor ovarian response	1 month

Trial Locations

Locations (1)

Clinica Eugin; 🇪🇸 Barcelona, Spain